Cargando…

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

BACKGROUND: HIV-1 infection generates numerous abnormalities in the B cell compartment which can be partly reversed by antiretroviral therapy. Our aim was to evaluate the effects that re-exposure to HIV antigens might have on the frequency and functionality of antibody secreting cells (ASC) in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llano, Anuska, Carrillo, Jorge, Mothe, Beatriz, Ruiz, Lidia, Marfil, Silvia, García, Elisabet, Yuste, Eloísa, Sánchez, Víctor, Clotet, Bonaventura, Blanco, Julià, Brander, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605223/ https://www.ncbi.nlm.nih.gov/pubmed/23433486 http://dx.doi.org/10.1186/1479-5876-11-48

Ejemplares similares

Modulation of antibody secreting cells and neutralizing Ab activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, A, et al.
Publicado: (2012)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Virological, Immune and Host genetics Markers in the Control of HIV Infection
por: Mothe, Beatriz, et al.
Publicado: (2009)

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
por: Carrillo, Jorge, et al.
Publicado: (2018)

Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller
por: Pernas, María, et al.
Publicado: (2012)

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
por: Carrillo, Jorge, et al.
Publicado: (2021)

Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
por: Olvera, Alex, et al.
Publicado: (2021)

Low levels of anti-MPER antibodies are detectable in viremic HIV infected
por: Carrillo, J, et al.
Publicado: (2012)

Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals
por: Carrillo, Jorge, et al.
Publicado: (2015)

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control
por: Oriol-Tordera, Bruna, et al.
Publicado: (2020)

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
por: Felip, Eudald, et al.
Publicado: (2022)

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity
por: Rosás-Umbert, Miriam, et al.
Publicado: (2022)

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination
por: Duran-Castells, Clara, et al.
Publicado: (2023)

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome
por: Oriol-Tordera, Bruna, et al.
Publicado: (2022)

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
por: Pradenas, Edwards, et al.
Publicado: (2021)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
por: Trinité, Benjamin, et al.
Publicado: (2021)

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
por: Clumeck, Nathan, et al.
Publicado: (2006)

Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells
por: Hendricks, Chynna M., et al.
Publicado: (2022)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
por: Pradenas, Edwards, et al.
Publicado: (2022)

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
por: Mothe, Beatriz, et al.
Publicado: (2015)

HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity
por: Pernas, Maria, et al.
Publicado: (2015)

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
por: Beltran-Pavez, Carolina, et al.
Publicado: (2022)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
por: Ainsua-Enrich, Erola, et al.
Publicado: (2022)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Small steps forward for HIV vaccine development
por: Mothe, Beatriz, et al.
Publicado: (2020)

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro
por: Olvera, Alex, et al.
Publicado: (2018)

Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations
por: Amengual-Rigo, Pep, et al.
Publicado: (2020)

Restricted infection of xenotropic murine leukemia virus-related virus in human lymphoid tissue
por: Curriu, Marta, et al.
Publicado: (2011)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
por: Cunyat, Francesc, et al.
Publicado: (2012)

T-Follicular-Like CD8(+) T Cell Responses in Chronic HIV Infection Are Associated With Virus Control and Antibody Isotype Switching to IgG
por: Romero-Martín, Luis, et al.
Publicado: (2022)

CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control
por: Mothe, Beatriz, et al.
Publicado: (2012)

Novel Nested Peptide Epitopes Recognized by CD4(+) T Cells Induced by HIV-1 Conserved-Region Vaccines
por: Borthwick, Nicola, et al.
Publicado: (2020)

Modeling Neutralization Kinetics of HIV by Broadly Neutralizing Monoclonal Antibodies in Genital Secretions Coating the Cervicovaginal Mucosa
por: McKinley, Scott A., et al.
Publicado: (2014)

Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk
por: Castilla, Joaquin, et al.
Publicado: (1998)

Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function
por: Curriu, Marta, et al.
Publicado: (2012)

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
por: Pradenas, Edwards, et al.
Publicado: (2023)

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity
por: Bonjoch, Anna, et al.
Publicado: (2016)

Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers
por: Rosás-Umbert, Miriam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lk17dc3vtbop9bavc9mqnmh700